Gapping down
In reaction to disappointing earnings/guidance:
- SSL -7.1%, HPE -6.5%, AGYS -5.7%, FL -4.8%, ROST -3%, CHUY -2.5%, PRSP -2.2%, INTU -1.6%, BKE -1.6%
Other news:
- GERN -27% (prices 107,049,375 shares of its common stock and pre-funded warrants to purchase 8,335,239 shares of common stock)
- CFRX -15.6% (prices offering of 11,797,752 shares of common stock and related warrants to purchase 8,848,314 shares of common stock with an exercise price of $4.90 per share, in exchange for consideration equating to $4.45 for one share of common stock and a warrant to purchase 0.75 shares of common stock)
- SNDX -14.6% (announces receipt of final results of E2112 trial; primary endpoint was not achieved)
- HOTH -11.7% (prices 1,818,182 shares of common stock at $2.75 per share)
- AMRN -10.7% (announces trial to evaluate effects of VASCEPA on patients with COVID-19)
- DVAX -9% (prices 14 mln shares of its common stock at $5.00 per share)
- PAE -5.9% (awarded $158 mln US Air Force contract)
- FIVN -1.6% (prices offering of $650 mln of 0.500% convertible senior notes due 2025)
Analyst comments:
- ACB -7.8% (downgraded to Underperform from Hold at Jefferies)
- ROKU -2.8% (downgraded to Equal-Weight from Overweight at Stephens)
- ZTO -2.2% (downgraded to Neutral from Overweight at JP Morgan)
- AINV -2.1% (downgraded to Sell from Neutral at Citigroup)
- OKE -2% (downgraded to Neutral from Overweight at JP Morgan)
- GLMD -1.7% (downgraded to Neutral from Buy at B. Riley FBR)